Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Stone, Lynnett
NCT05630872: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis	Active, not recruiting	2	30	RoW	Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, DTG 50 mg orally QD plus TDF/3TC, 2HPZM, 2HPM	National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Mylan Inc.	HIV-associated Tuberculosis	02/25	09/25
HVTN605A5421, NCT05947890: Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa	Recruiting	2	276	RoW	MTBVAC, BCG	HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), Biofabri, S.L	HIV I Infection, Tuberculosis	02/26	02/26